- This event has passed.
Talking Point Tuesdays – NICE: Making an Early Assessment
February 18 @ 9:00 am - 12:00 pm
Join us on Tuesday 18th February at 09:00 AM at The Catalyst (10:00AM for online attendees) for a morning of insightful discussions and networking opportunities. At this exciting event, you’ll learn about NICE (National Institute for Health and Care Excellence) and hear about some key updates.
Background
The Innovation Observatory is the gateway to the NICE Technology Assessment (TA) Programme for industry, preventing delays in bringing new and repurposed medicines to the UK market through the early identification and tracking of new and repurposed medicines and health technologies.
The National Institute for Health and Care Excellence (NICE) TA programme provides UK healthcare guidance through Technology Appraisals and Highly Specialised Technologies assessments. A NICE recommendation is crucial for market access to the NHS in England and Wales. The Innovation Observatory is the first step in the process and we work closely with our pharmaceutical industry partners.
We provide the ‘gateway’ to NICE by submitting potential topics that meet the NICE Topic Selection criteria for medicines as set out in the NICE Topic Selection Manual. We follow the development of new and repurposed medicines from at least two years before estimated UK license to provide a timely notification to NICE. This early notification triggers the NICE TA process and allows NICE to provide new guidelines as close to the license date as possible.
The Innovation Observatory has a strict confidentiality agreement which means we only share confidential information with selected policymakers.
Sign up to this informative event
With a range of knowledgeable speakers and an expert panel available for your questions – don’t miss out on this fantastic opportunity!
This event is funded by NIHR and free to attend. Attendance is available either online or in -person at The Catalyst in Newcastle. It is open to nationwide small and medium sized businesses operating in the health and life sciences sector.